Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00565864 · ClinicalTrials.gov registry record · Phase 4

Neurocognitive and Metabolic Effects of Mild Hypothyroidism

A Phase 4 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 4
Development phase
173
Enrollment target

NCT00565864: Completed Phase 4 study, sponsored by Oregon Health and Science University.

NCT00565864 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 173 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00565864, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 4
Development phase
173 participants
Enrollment target

Study Summary

Patients with hypothyroidism are routinely treated with thyroid hormone (l-thyroxine) for replacement therapy. Physicians monitor the thyroid hormone dose by measuring a thyroid stimulating hormone (TSH) level in the blood, with the goal of a normal level. However, recent data suggest that the "normal" TSH range is too broad, and that patients may still have symptoms if their TSH levels are at the top or bottom part of the normal range. To study this issue, it is useful to address issues such as general health status, psychological symptoms, mood, memory, and metabolic status, since thyroid hormone has major effects on the brain and metabolism, and since patients with treated hypothyroidism often have symptoms related to these areas. In the present study, otherwise healthy subjects with treated hypothyroidism, ages 20-75 years, will be enrolled in a 7-11month study. At baseline, they will have tests of health status, psychological symptoms, mood, memory, body composition, and energy expenditure performed. Following these baseline measurements, subjects will receive either their usual doses of l-thyroxine, or a slightly higher or lower dose. The doses will be chosen to try to achieve either a low-normal TSH level, a high-normal TSH level, or a mildly elevated TSH level. Which target TSH the patient is assigned will be determined randomly, and neither the subject nor the study contacts will know which dose the patient is receiving. Subjects will be seen every 6 weeks during the study for brief visits to make sure they are not having any side effects, and to adjust the l-thyroxine doses if the TSH has not yet reached the target range. At the 24-week visit (end of study), the subjects will undergo the same tests that they had on the baseline visit. Results from the study will be examined to see if minor changes in TSH or other thyroid hormone levels cause changes in any of the outcomes, and if the degree of TSH change correlates with the degree of outcome changes. Th

Primary Outcome

Iowa Gambling Task Net-5. Four decks of cards are shown face down on a computer screen. The subject chooses cards from any deck, resulting in the gain or loss of money. The subject is unaware that 2 decks are advantageous (small gains, smaller losses), while 2 are disadvantageous (large gains, larger losses). The subject's choices are classified as advantageous (X) or disadvantageous (Y), with a net score of X-Y, over 5 trials of 100 cards each. The outcome reported here is the score on the fift

Interventions

  • DRUG L-thyroxine (L-T4)

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2008-08
Est. Completion 2013-08
Phase Phase 4

What the finished NCT00565864 record still lists

NCT00565864 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which L-thyroxine (L-T4) is the first listed.

NCT00565864 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00565864 about?

NCT00565864 is a clinical study titled "Neurocognitive and Metabolic Effects of Mild Hypothyroidism". Patients with hypothyroidism are routinely treated with thyroid hormone (l-thyroxine) for replacement therapy. Physicians monitor the thyroid hormone dose by measuring a thyroid stimulating hormone (TSH) level in the blood, with the goal of a normal level. However, recent data suggest that the "norm...

What is the current status of trial NCT00565864?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2008-08. Estimated completion is 2013-08.

What interventions are being tested in trial NCT00565864?

The interventions under investigation include: L-thyroxine (L-T4) (DRUG).

Who is sponsoring clinical trial NCT00565864?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00565864's enrollment target sits among peer trials

173 481st of 2000 higher than 1,520 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05568719 · 173 participants · Phase 3

    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

  • NCT07070115 · 173 participants · NA

    Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

  • NCT07150832 · 173 participants · NA

    Efficacy of the I-CARE Digital Health Intervention

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00565864, the US trial registry maintained by the National Library of Medicine. NCT00565864 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.